# Phase I Trial of PX-478

> **NCT00522652** · PHASE1 · COMPLETED · sponsor: **Cascadian Therapeutics Inc.** · enrollment: 45 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Lymphoma

## Interventions

- **DRUG:** PX-478

## Key facts

- **NCT ID:** NCT00522652
- **Lead sponsor:** Cascadian Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2018-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00522652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00522652, "Phase I Trial of PX-478". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00522652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*